Six Hours on Psychedelics: Multi-Site Course Boosts Psychiatry Trainees’ Knowledge and Counseling Confidence

Psychedelic medicine has moved from the fringes of psychiatry into the mainstream of clinical research, with psilocybin therapies advancing toward potential regulatory decisions and major medical centers opening dedicated trials. Yet the physicians who will ultimately sit across from patients asking about these treatments—psychiatry residents—have consistently reported that their formal education on the topic is thin to nonexistent. A new study published in Academic Psychiatry by Mary E. Yaden of Johns Hopkins University School of Medicine and colleagues now offers one of the clearest multi-institutional answers to that gap, showing that a compact, standardized six-hour curriculum can measurably improve trainees’ knowledge and, perhaps most importantly, their confidence in counseling patients about psychedelic treatments.

The study was designed as a brief report but carries outsized practical significance. Between 2025 and 2026, the research team delivered an identical course across four psychiatry residency programs in the Northeastern United States, allowing them to evaluate whether the educational effect held across different institutions, faculty cultures, and trainee cohorts. This multi-site approach matters because single-site curriculum evaluations can be confounded by local enthusiasm, a charismatic lecturer, or an unusually motivated group of residents. By replicating the intervention at four programs, the authors strengthened the case that the improvements they observed reflect the curriculum itself rather than idiosyncrasies of any one training environment.

The curriculum was organized into six modules delivered over six hours, covering foundational concepts and evidence as well as clinical considerations. That structure followed the well-established six-step approach to curriculum development for medical education articulated by Thomas, Kern, and Hughes, a framework widely used in graduate medical education. The modules moved residents from basic pharmacology and history through the current state of clinical trial evidence, and then into the practical territory that residents will actually encounter in clinics and emergency departments: what the evidence supports, what it does not, and how to talk to patients who arrive with questions shaped by media coverage, anecdote, or marketing.

Assessment was built into the design from the start. Participants completed anonymous pre-course surveys before the first module and post-course surveys after the final one. Of the forty trainees who participated across the institutions, thirty-four completed the pre-course survey and twenty-two completed the post-course survey—a retention pattern typical of voluntary educational evaluations in busy residency programs, though one that the authors appropriately acknowledge in interpreting the results. The surveys captured three distinct dimensions: self-assessed knowledge, performance on a knowledge quiz, and confidence in counseling patients across specific domains including clinical research, harm reduction, and treatment risks.

The baseline findings were as revealing as the outcomes. Most trainees reported minimal prior didactic exposure to psychedelic medicine, confirming what earlier survey work had suggested. A previous study by the same research group, published in International Review of Psychiatry, surveyed psychiatric residency program directors and documented how rarely formal psychedelic content appears in accredited training. Other work by Barnett and colleagues found that psychiatrists at professional conferences reported limited knowledge of the field, and a 2025 survey in the Journal of Psychoactive Drugs concluded that trainees feel unprepared for advances in psychedelic medicine. The new study’s baseline data place four residency programs squarely within that national pattern.

After the course, the changes were statistically significant on the measures that matter most for clinical readiness. Self-assessed knowledge improved, and so did scores on the objective knowledge quiz, indicating that the gains were not merely an illusion of confidence. Trainees also rated their understanding of two complementary concepts more highly: the rationale for psychedelic treatments and the limitations of the evidence base. That pairing is deliberate and pedagogically important. A curriculum that teaches only mechanisms and promises risks producing uncritical enthusiasm; one that teaches only skepticism risks leaving physicians unable to engage with a fast-moving scientific literature. Measuring both dimensions suggests the course designers aimed for calibrated judgment rather than advocacy.

The most substantial improvements, according to the authors, appeared in counseling confidence. Residents reported greater confidence across domains covering clinical research—helping patients interpret what a trial result does and does not mean—along with harm reduction, a framework for reducing negative consequences of substance use that many patients will ask about as access expands, and treatment risks, including the psychiatric and physiological considerations that accompany serotonergic hallucinogens. For trainees who may soon face patient questions in routine appointments, this shift from abstract knowledge to practical conversational competence is arguably the study’s central contribution.

Just as telling is what did not change. Baseline interest in psychedelic medicine was already high when residents began the course, and it did not increase significantly afterward. Nor did the course significantly alter trainees’ plans to pursue opportunities in the field. The authors interpret this null result as a feature rather than a failure: the curriculum improved knowledge and counseling skills without overinflating enthusiasm for psychedelics as a clinical enterprise. In an area of medicine where public hype has at times outrun the evidence, an educational intervention that raises competence while leaving excitement levels untouched represents a meaningful calibration achievement. It suggests the course functioned as science education rather than promotion.

The findings arrive at a pivotal moment for the field. Regulatory decisions on psilocybin-based therapies for depression are advancing, clinical trials continue to multiply, and thePsychedelic Education Partnership launched in March 2026 with the explicit goal of advancing evidence-based education for the healthcare workforce. Meanwhile, the funding landscape reflects growing institutional seriousness: the curriculum described in this study was developed with support from the Heffter Research Institute, a long-established funder of psychedelic research, specifically to create residency and fellowship teaching materials. The study team spanned Johns Hopkins, NYU Grossman School of Medicine, Yale, Columbia, the New York State Psychiatric Institute, the University of Vermont, King’s College London, and Stanford, indicating the depth of academic investment in training infrastructure.

Limitations remain and deserve attention. The sample of forty trainees, with twenty-two completing post-course assessment, is modest, and the anonymous survey design, while ethically appropriate and exempted from full-board review by the Johns Hopkins Institutional Review Board, cannot track individual knowledge retention over time. The study measured immediate post-course outcomes rather than durable learning months later, and it assessed one region of the United States. Still, the multi-site consistency of the improvements, the alignment between subjective and objective knowledge gains, and the carefully preserved baseline of enthusiasm together make a strong case that standardized psychedelic medicine curricula can be implemented at scale. As patients increasingly bring questions about psilocybin, MDMA-assisted therapy, and related treatments into psychiatric offices, the study suggests that the answer to the training gap need not be a full semester of coursework—six well-designed hours, replicated across institutions, may be enough to prepare residents for the conversations they will actually have. For residency programs weighing whether and how to add this content, the study provides a template, an assessment framework, and evidence that the investment pays off in exactly the competence that clinical practice will demand.

Subject of Research: Evaluation of a standardized psychedelic medicine curriculum for psychiatry residents across four U.S. residency programs

Article Title: A Multi-Site Evaluation of a Psychedelic Medicine Curriculum for Psychiatry Trainees

Article References: Yaden, M. E., O’Donnell, K. C., Roberts, D. E., Goldway, N., Tiwari, P., Ching, T. H. W., Hokanson, J., Gukasyan, N., Appold, B., Glick, G., Kelmendi, B., Ross, S., & Pittenger, C. (2026). A Multi-Site Evaluation of a Psychedelic Medicine Curriculum for Psychiatry Trainees. Academic Psychiatry. https://doi.org/10.1007/s40596-026-02444-3

Image Credits: AI Generated

DOI: 10.1007/s40596-026-02444-3

Keywords: psychedelic medicine, psychiatry residency, medical education, psilocybin, curriculum evaluation, harm reduction, counseling confidence, graduate medical education, psychopharmacology, clinical trials, trainee knowledge, Academic Psychiatry